använder sig av cookies för att ge dig som besökare en så bra upplevelse som möjligt.

Corporate Finance

Vator Securities focuses on identifying and financing growth companies as they expand and develop into tomorrow’s market leaders.

read more

Equity Research

Commissioned research by Vator Securities is offered to selected life science companies – "By Invitation Only". Commissioned researches are published continuously.

read more

Vator Securities Unicorn Summit was held on November 27th 2019 at IVA Conferens Center in Stockholm and was attended by over 200 guests.

Click here to watch the presentations

CREATE Health delivers another exciting tech, ProMIS, which potentially could open up a world of new IP for Immunovia

In our latest research update on Immunovia, we presented our forecast of a future diagnostic regimen including a combination of proteomics and genomics-based techs to generate timely and correct diagnosis of cancer.

Published in the impactful Nature Communication Biology, Immunovia’s research arm and collaborator CREATE Health demonstrates the powerful combination of the two techs in its novel academic research project, the ProMIS platform.

read more

No one-trick pony – advancing a novel platform-based CNS company

AlzeCure has with its seven-project portfolio multiple shots at goal where each, while early stage, represents a potential multibillion-dollar opportunity.

We update our rating to Outperform and raise the target price to SEK 16 per share, corresponding to an equity value of approximately SEK 600m non-diluted, derived from risk-adjusted DCF valuation of ACD856 and ACD440. 

read more

When genomics and proteomics converge, Immunovia will probably be snatched up

By being at the forefront of proteomics-based technology, nearing launch of the first to market, outstandingly accurate blood-based test for early detection of pancreatic cancer, we see Immunovia as an apparent strategic target for acquisition.

We maintain the Outperform rating and raise the target price to 300 SEK per share, corresponding to an equity value of SEK 6.8 bn non-diluted, derived from a DCF valuation of the opportunity in pancreatic cancer.

read more

Vator Securities rådger Xintela i 40,5 MSEK företrädesemission

Vator Securities agerar som finansiell rådgivare i samband med transaktionen om SEK 40,5 miljoner.

Xintela är en innovatör i utvecklingen avregenerativa cellterapier och riktade cancerterapier baserade på denpatenterade markörteknologiplattformen XINMARK®.

read more

More News